University of Iowa Hospitals and Clinics - Oncology
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bushnell, David
ACTION-1, NCT05477576 / 2022-000507-12: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc., RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
12/25
07/28
LUMOD-ID, NCT06395402: 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Recruiting
2
120
US
Lutetium Lu 177 dotatate therapy, Lutathera
University of Iowa, Novartis
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
12/29
12/29
Heroine01, NCT04469127: A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.

Not yet recruiting
1/2
100
RoW
Lutetium-177-DOTAGA-IAC
Advanced Imaging Projects, LLC, University of Witwatersrand, South Africa, Postgraduate Institute of Medical and Research
Breast Cancer Stage IV
08/25
08/25
SPORE-3, NCT04614766: A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Withdrawn
1/2
50
US
Lutathera, lutetium Lu 177 dotatate, Azedra, iobenguane I-131
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Progenics Pharmaceuticals, Inc.
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
04/24
04/24
NCT03335670: Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Active, not recruiting
1
30
US
[68Ga]Pentixafor, (68Ga)pentixafor
Yusuf Menda, National Cancer Institute (NCI), National Institutes of Health (NIH), Holden Comprehensive Cancer Center
Neuroendocrine Tumors
12/26
12/27
NCT06148636: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Active, not recruiting
1
24
US
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
David Bushnell, Holden Comprehensive Cancer Center, National Cancer Institute (NCI), Perspective Therapeutics
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
11/26
11/27
NCT03044977: Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Active, not recruiting
1
20
US
90Y-DOTA-3-Tyr-Octreotide, 90Y DOTATOC, 131I-MIBG
David Bushnell, National Institutes of Health (NIH), National Cancer Institute (NCI), Holden Comprehensive Cancer Center
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
12/25
12/27
NCT05557708: A Safety Study of 212Pb-Pentixather Radioligand Therapy

Not yet recruiting
1
20
US
212-Lead Pentixather, 203-Lead Pentixather SPECT/CT
Yusuf Menda, National Institutes of Health (NIH), National Cancer Institute (NCI), Holden Comprehensive Cancer Center
Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung
06/26
06/28

Download Options